Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The company’s lead treatment for the Hepatitis C Virus infection is currently in a Phase I trial. Idera is collaborating with Novartis International Pharmaceutical, Ltd. for the discovery, development, and commercialization of TLR9 agonists for the treatment of asthma and allergy indications, and with Merck & Co., Inc. for the use of Idera’s TLR7, 8 and 9 agonists in combination with Merck & Co.’s therapeutic and prophylactic vaccines in the areas of oncology, infectious diseases, and Alzheimer’s disease.
Changed name to Aceragen, Inc. from Idera Pharmaceuticals, 1/23/2023.
Changed name to Idera Pharmaceuticals, Inc. from Aceragen, Inc., 1/17/2023.